Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

124.99 -3.08 (-2.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
68 69 Next >
News headline image
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns ↗
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely... 
Via Benzinga
News headline image
(GILD) - Analyzing Gilead Sciences's Short Interest ↗
 
Via Benzinga
News headline image
Nasdaq 100 Alert: 7 Undervalued Tech Stocks Ready to Rocket in 2024 ↗
Despite the gains of last year there are still many undervalued tech stocks on the Nasdaq 100 waiting to explode higher in 2024 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,100 Today ↗
 
Via Benzinga
News headline image
A Look Into Gilead Sciences Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
(GILD) - Analyzing Gilead Sciences's Short Interest ↗
 
Via Benzinga
News headline image
The 500 Top Stocks to Buy for 2024, Ranked by AI ↗
These are the very best stocks to buy for 2024 for any investor, according to Tom Yeung's MarketMasterAI system. 
Via InvestorPlace
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. 
Via Benzinga
News headline image
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
News headline image
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’ ↗
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone." 
Via InvestorPlace
News headline image
Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today? ↗
Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million,  
Via Benzinga
News headline image
Why Is Hookipa Pharma (HOOK) Stock Up 81% Today? ↗
Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK. 
Via InvestorPlace
News headline image
RedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola ↗
RedHill Biopharma Ltd (NASDAQ: RDHL) says opaganib and RHB-107 (upamostat) demonstrated robust synergistic effects when combined individually with Gilead Sciences Inc (NASDAQ: GILD) Veklury... 
Via Benzinga
News headline image
QQQ And QQQM ETFs Top Gainers And Laggards Of 2023 ↗
This article will look at the top gainers and laggards of the two popular ETFs, which have over $17 billion and $223 billion assets, respectively. The two funds are similar, with the only difference... 
Via Talk Markets
Topics ETFs
News headline image
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
News headline image
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? ↗
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the  
Via Benzinga
News headline image
Why Is Compugen (CGEN) Stock Up 189% Today? ↗
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences. 
Via InvestorPlace
News headline image
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy. ↗
Lilly's weight loss drug appears to be on the way to becoming a megablockbuster. 
Via The Motley Fool
News headline image
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
News headline image
NASDAQ:GILD is probably undervalued for the fundamentals it is displaying. ↗
Investors should take notice ofGILEAD SCIENCES INC (NASDAQ:GILD)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street ↗
There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock. 
Via The Motley Fool
News headline image
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions ↗
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion... 
Via Benzinga
News headline image
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.